CSF-1r inhibitor pharmaceutical composition, preparation method therefor and pharmaceutical use thereof

By optimizing the prescription ingredients of the drug preparation, the liquidity and bulk density of the CSF-1R inhibitor drug are solved, the fluidity and discharge uniformity of the drug composition are improved, and the needs of clinical research and drug marketing are met.

WO2024245340A1PCT designated stage expired Publication Date: 2024-12-05ABBISKO THERAPEUTICS CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/096336
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

CSF-1R inhibitor The compound of formula (I) has poor fluidity and low bulk density, which cannot meet the requirements of GMP production and capsule filling, resulting in large amounts of differences in volume and cannot meet the needs of clinical research and drug marketing.

Method used

By optimizing the prescription ingredients of drug preparations, using appropriate diluents, glidants, lubricants and disintegrants, adjusting the proportions, improving the flowability and color uniformity of the drug, and developing a prescription that meets clinical requirements for dissolution effects, suitable for use in the use of suitable diluents, glidants, lubricants and disintegrants. Industrialized production.

Benefits of technology

It improves the fluidity and discharge uniformity of the pharmaceutical composition, reduces the risk of volume differences, meets the requirements of capsule filling, and ensures the clinical research and marketing needs of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024096336_05122024_PF_FP_ABST
    Figure CN2024096336_05122024_PF_FP_ABST
Patent Text Reader

Abstract

A CSF-1R inhibitor pharmaceutical composition, a preparation method therefor and a pharmaceutical use thereof. The CSF-1R inhibitor composition comprises a free base of a compound of formula (I) having the following structure or an acid salt of the compound as an active ingredient. A suitable diluent and other pharmaceutically acceptable carriers are used, and the fluidity and the color uniformity of the active pharmaceutical ingredient powder are improved by adjusting the prescription components of a pharmaceutical preparation, so as to obtain a prescription and a pharmaceutical preparation.
Need to check novelty before this filing date? Find Prior Art

Description

CSF-1R inhibitor pharmaceutical composition, preparation method and pharmaceutical application thereof Technical Field

[0001] The present invention belongs to the field of drug development, and in particular relates to a CSF-1R inhibitor pharmaceutical composition, a preparation method thereof and pharmaceutical applications. Background Art

[0002] CSF-1R (cFMS) stands for colony-stimulating factor-1 receptor. CSF-1R, along with cKIT, FLT3, and PDGFR-a&b, belongs to the family of three growth hormone receptors. This receptor is a membrane protein expressed on the surface of macrophages and monocytes. Its extracellular domain binds to macrophage colony-stimulating factor, while its intracellular tyrosine kinase activates downstream cell growth and proliferation signaling pathways in macrophages and monocytes, including MAPK and PI3K. Therefore, the CSF-1R signaling pathway has a significant impact on the development and differentiation of macrophages and monocytes, as well as the physiological functions of tumor-associated macrophages (TAMs).

[0003] With the progress of tumor immunotherapy in recent years, tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are believed to be directly related to the formation of an immunosuppressive microenvironment within the tumor and angiogenesis that supports tumor growth. At the same time, clinical studies have shown that the content of TAMs is negatively correlated with the prognosis of cancer patients. In vivo efficacy experiments in mice have shown that inhibiting the CSF-1R signaling pathway can significantly reduce the number of macrophages in the tumor that suppress the immune system and increase the content of CD8-positive T cells. These experimental results indicate that CSF-1R small molecule inhibitors may reverse the immunosuppressive environment within the tumor, promote the activation of the immune system, and prolong the lives of cancer patients.

[0004] Shanghai Abbisko Therapeutics Co., Ltd. has discovered a small molecule compound with CSF-1R inhibitory effects during its long-term research (WO2018214867 A1, international publication date: November 29, 2018). Representative compounds are as follows:

[0005] The Chinese name is: 3,3-dimethyl-N-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)-2-oxopyrrolidine-1-carboxamide (referred to as the compound of formula (I) or the free base of the compound of formula (I)). This compound can significantly enhance the inhibitory effect on the CSF-1R target and the selectivity for other kinase receptors, thereby increasing the therapeutic window and reducing clinical toxic side effects. It can be used for the targeted treatment of tumors such as lung cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, melanoma, pancreatic cancer, head and neck cancer, glioma, and tendon sheath giant cell tumor.

[0006] However, during later pharmaceutical research, it was discovered that the free base of the compound of formula (I) had poor fluidity and a low bulk density, which did not meet the requirements of GMP production. This also resulted in a risk of large volume variations during capsule filling, which did not meet the requirements of capsule filling. Therefore, there is an urgent need to develop a pharmaceutical composition and formulation process that overcomes these technical deficiencies and meets the needs of clinical research and drug marketing for the compound of formula (I).

[0007] Summary of the Invention

[0008] The purpose of the present invention is to provide a CSF-1R inhibitor pharmaceutical composition to solve the problem of drug accessibility and meet the needs of clinical research and drug marketing of the compound of formula (I).

[0009] In order to solve the problems existing in the prior art, the inventors adopted suitable diluents, optimized the types and proportions of drug carriers such as glidants, lubricants and disintegrants, and improved the fluidity and color uniformity of the raw material powder by adjusting the prescription ingredients of the drug preparation. They also researched and developed a prescription with a dissolution effect that meets clinical needs. All physicochemical properties meet clinical requirements, and further obtained a prescription with good discharge and / or capsule filling uniformity. This prescription and its preparation process are suitable for industrial production and can meet the needs of clinical research and drug marketing of the compound of formula (I).

[0010] The first aspect of the present invention provides a pharmaceutical composition comprising a free base of a compound of formula (I) or an acid salt thereof as an active ingredient, a pharmaceutically acceptable diluent, and other pharmaceutically acceptable carriers, wherein the other pharmaceutically acceptable carriers are one or more of a glidant, a lubricant, and a disintegrant.

[0011] As a preferred embodiment, the acid salt of the compound of formula (I) is selected from hydrochloride, sulfate, hydrobromide, hydrofluoride, hydroiodide, phosphate, acetate, dichloroacetate, trichloroacetate, trifluoroacetate, benzenesulfonate, p-toluenesulfonate, 4-chlorobenzenesulfonate, 1,5-naphthalene disulfonate, naphthalene-2-sulfonate, ethane-1,2-disulfonate, methanesulfonate, ethanesulfonate, benzoate, decanoate, hexanoate, caprylate, cinnamate, citrate, cyclohexanesulfamate, camphorsulfonate, aspartate, camphorate, gluconate, glucuronate, glutamate, isoascorbate, lactate, aspartate, malate, mandelate, pyroglutamate, tartaric acid salt, lauryl sulfate, dibenzoyltartrate, formate, fumarate, galactonate, gentisate, acetohydroxamate, malonate, succinate, glutarate, adipate, sebacate, 2-ketoglutarate, glycolate, hippurate, isethionate, lactobionate, ascorbate, aspartate, laurate, camphorate, maleate, nicotinate, oleate, orotate, oxalate, palmitate, pamoate, propionate, 4-acetamidobenzoate, 4-aminobenzoate, salicylate, 4-aminosalicylate, 2,5-dihydroxybenzoate, 1-hydroxy-2-naphthoate, stearate, thiocyanate, undecylenate, or succinate.

[0012] As a further preferred embodiment, the acid salt of the compound of formula (I) is selected from hydrochloride, sulfate, phosphate, methanesulfonate, citrate, malate, fumarate or tartrate.

[0013] As a preferred embodiment, the active ingredient is also an anhydrate, hydrate or solvate of the free base of the compound of formula (I) or its acid salt.

[0014] As a further preferred embodiment, the active ingredient is a solvate of the free base of the compound of formula (I) or an acid salt thereof, and the solvent is selected from alcohols, chloroalkanes, ketones, ethers, cyclic ethers, esters, alkanes, cycloalkanes, benzenes, amides, sulfoxides, organic solvents, or mixtures thereof, or aqueous solutions thereof.

[0015] As a further preferred embodiment, the solvent is selected from methanol, ethanol, n-propanol, isopropanol, dichloromethane, acetonitrile, acetone, 1,4-dioxane, tetrahydrofuran, N,N-dimethylformamide, ethyl acetate, isopropyl acetate, methyl tert-butyl ether, 2-methoxyethyl ether or a mixture thereof, or an aqueous solution thereof.

[0016] As a further preferred embodiment, the active ingredient is a hydrate of a free base or an acid salt thereof, and each molecule of the hydrate contains 1 to 3 water molecules.

[0017] As a further preferred embodiment, the active ingredient is a free base or an anhydrate or hydrate of an acid salt thereof.

[0018] As a further preferred embodiment, the active ingredient is a free base or an anhydrous form of an acid salt thereof.

[0019] As a further preferred embodiment, the active ingredient is a hydrate of a free base or an acid salt thereof, and each molecule of the hydrate contains one water molecule.

[0020] As a preferred embodiment, the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I), and the pharmaceutical composition contains 0.1% to 60.0% W / W of the active ingredient relative to the total weight of the composition.

[0021] As a further preferred embodiment, the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I), and the pharmaceutical composition contains 1.0% to 40.0% W / W of the active ingredient relative to the total weight of the composition.

[0022] As a further preferred embodiment, the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I), and the pharmaceutical composition contains 3.0% to 32.0% W / W of the active ingredient relative to the total weight of the composition.

[0023] As a preferred solution, the diluent is one or more of lactose, lactose hydrate and microcrystalline cellulose.

[0024] As a further preferred embodiment, the pharmaceutical composition comprises 40.0% to 99.9% W / W of diluent relative to the total weight of the composition.

[0025] As a further preferred embodiment, the pharmaceutical composition comprises 50.0% to 94.0% W / W of diluent relative to the total weight of the composition.

[0026] As a further preferred embodiment, the pharmaceutical composition comprises 60.0% to 92.0% W / W of diluent relative to the total weight of the composition.

[0027] As a further preferred embodiment, the diluent is a mixture of lactose monohydrate and microcrystalline cellulose, and the W / W mass ratio of the lactose monohydrate to the microcrystalline cellulose is 1:5 to 5:1.

[0028] As a further preferred solution, the W / W mass ratio of the lactose monohydrate to the microcrystalline cellulose is 1:3 to 3:1.

[0029] As a further preferred solution, the W / W mass ratio of the lactose monohydrate to the microcrystalline cellulose is 1:1 to 3:1.

[0030] As a further preferred embodiment, the lactose monohydrate is lactose monohydrate T80 or lactose monohydrate 316; and the microcrystalline cellulose is microcrystalline cellulose PH102 or microcrystalline cellulose PH101.

[0031] As a further preferred solution, the diluent is a mixture of lactose monohydrate T80 and microcrystalline cellulose PH102, and the W / W mass ratio of the lactose monohydrate T80 and microcrystalline cellulose PH102 is 1:5 to 5:1.

[0032] As a further preferred solution, the W / W mass ratio of the lactose monohydrate T80 and the microcrystalline cellulose PH102 is 1:3 to 3:1.

[0033] As a further preferred solution, the W / W mass ratio of the lactose monohydrate T80 and the microcrystalline cellulose PH102 is 1:1 to 3:1; more preferably 2:1 or 3:1.

[0034] As a further preferred solution, the diluent is a mixture of lactose monohydrate T80 and microcrystalline cellulose PH101, and the W / W mass ratio of the lactose monohydrate T80 and microcrystalline cellulose PH101 is 1:5 to 5:1.

[0035] As a further preferred solution, the W / W mass ratio of the lactose monohydrate T80 and the microcrystalline cellulose PH101 is 1:3 to 3:1.

[0036] As a further preferred solution, the W / W mass ratio of the lactose monohydrate T80 and the microcrystalline cellulose PH101 is 1:1 to 3:1; more preferably 2:1 or 3:1.

[0037] As a further preferred solution, the diluent is a mixture of lactose monohydrate 316 and microcrystalline cellulose PH102, and the W / W mass ratio of the lactose monohydrate 316 and microcrystalline cellulose PH102 is 1:5 to 5:1.

[0038] As a further preferred solution, the W / W mass ratio of the lactose monohydrate 316 and the microcrystalline cellulose PH102 is 1:3 to 3:1.

[0039] As a further preferred solution, the W / W mass ratio of the lactose monohydrate 316 and the microcrystalline cellulose PH102 is 1:1 to 3:1; more preferably 2:1 or 3:1.

[0040] As a further preferred solution, the diluent is a mixture of lactose monohydrate 316 and microcrystalline cellulose PH101, and the W / W mass ratio of the lactose monohydrate 316 and microcrystalline cellulose PH101 is 1:5 to 5:1.

[0041] As a further preferred solution, the W / W mass ratio of the lactose monohydrate 316 and the microcrystalline cellulose PH101 is 1:3 to 3:1.

[0042] As a further preferred solution, the W / W mass ratio of the lactose monohydrate 316 and the microcrystalline cellulose PH101 is 1:1 to 3:1; more preferably 2:1 or 3:1.

[0043] As a preferred solution, the glidant is one or more of colloidal silicon dioxide, precipitated silicon dioxide and talc.

[0044] As a further preferred embodiment, the glidant is colloidal silicon dioxide.

[0045] As a further preferred solution, the glidant is colloidal silicon dioxide 200.

[0046] As a preferred solution, the glidant is one or more of colloidal silicon dioxide, precipitated silicon dioxide and talc, and the pharmaceutical composition contains 0.1% to 10.0% W / W of the glidant relative to the total weight of the composition.

[0047] As a further preferred embodiment, the glidant is colloidal silicon dioxide, and the glidant comprises 0.5% to 5.0% W / W relative to the total weight of the composition.

[0048] As a further preferred embodiment, the glidant is colloidal silicon dioxide, and the glidant content is 1.0% to 3.0% W / W relative to the total weight of the composition.

[0049] As a further preferred embodiment, the glidant is colloidal silicon dioxide, and the glidant content is 1.0% to 2.0% W / W relative to the total weight of the composition.

[0050] As a preferred solution, the glidant is colloidal silicon dioxide 200, and the pharmaceutical composition contains 0.1% to 10.0% W / W of the glidant relative to the total weight of the composition.

[0051] As a further preferred embodiment, the glidant is colloidal silicon dioxide 200, and the pharmaceutical composition comprises 0.5% to 5.0% W / W of the glidant relative to the total weight of the composition.

[0052] As a further preferred embodiment, the glidant is colloidal silicon dioxide 200, and the pharmaceutical composition comprises 1.0% to 3.0% W / W of the glidant relative to the total weight of the composition.

[0053] As a further preferred embodiment, the glidant is colloidal silicon dioxide 200, and the pharmaceutical composition comprises 1.0% to 2.0% W / W of the glidant relative to the total weight of the composition.

[0054] As a preferred embodiment, the lubricant is one or more of magnesium stearate, sodium stearyl fumarate, glyceryl dibehenate, colloidal silicon dioxide, talc, other hydrogenated vegetable oils and triglycerides, and the pharmaceutical composition contains 0.1% to 5.0% W / W of the lubricant relative to the total weight of the composition.

[0055] As a further preferred embodiment, the lubricant is one or more of magnesium stearate, sodium stearyl fumarate, and glyceryl dibehenate, and the lubricant is contained in an amount of 0.5% to 2.0% W / W relative to the total weight of the composition.

[0056] As a preferred solution, the lubricant is magnesium stearate or sodium stearyl fumarate, and the pharmaceutical composition contains 0.1% to 5.0% W / W of the lubricant relative to the total weight of the composition.

[0057] As a further preferred embodiment, the lubricant is magnesium stearate or sodium stearyl fumarate, and the lubricant is contained in an amount of 0.5% to 2.0% W / W relative to the total weight of the composition.

[0058] As a further preferred solution, the lubricant is magnesium stearate or sodium stearyl fumarate, and the lubricant is contained in an amount of 0.5% to 1.5% W / W relative to the total weight of the composition.

[0059] As a preferred embodiment, the disintegrant is one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone, sodium starch glycolate and the like.

[0060] As a further preferred embodiment, the disintegrant is croscarmellose sodium.

[0061] As a preferred embodiment, the disintegrant is one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinyl pyrrolidone, sodium starch glycolate and their analogs, and the pharmaceutical composition contains 0.1% to 10.0% W / W of the disintegrant relative to the total weight of the composition.

[0062] As a preferred embodiment, the disintegrant is croscarmellose sodium, and the pharmaceutical composition contains 0.1% to 10.0% W / W of the disintegrant relative to the total weight of the composition.

[0063] As a further preferred embodiment, the disintegrant is croscarmellose sodium, and the pharmaceutical composition comprises 0.5% to 5.0% W / W of the disintegrant relative to the total weight of the composition.

[0064] As a further preferred embodiment, the disintegrant is croscarmellose sodium, and the pharmaceutical composition contains 1.0% to 5.0% W / W of the disintegrant relative to the total weight of the composition.

[0065] As a preferred embodiment, the pharmaceutical composition comprises an active ingredient and a diluent, and the W / W mass ratio thereof is (1.0 to 50.0): (50.0 to 94.0), and the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I); the diluent is lactose monohydrate and microcrystalline cellulose, and the W / W mass ratio thereof is 1:1 to 3:1.

[0066] As a preferred embodiment, the pharmaceutical composition comprises an active ingredient and a diluent, and the W / W mass ratio thereof is (1.0-50.0): (60.0-92.0), and the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I); the diluent is lactose monohydrate T80 and microcrystalline cellulose PH102, and the W / W mass ratio thereof is 1:1-3:1.

[0067] As a preferred embodiment, the pharmaceutical composition comprises an active ingredient and a diluent, and the W / W mass ratio thereof is (1.0-50.0): (60.0-92.0), and the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I); the diluent is lactose monohydrate T80 and microcrystalline cellulose PH101, and the W / W mass ratio thereof is 1:1-3:1.

[0068] As a preferred embodiment, the pharmaceutical composition comprises an active ingredient and a diluent, and the W / W mass ratio thereof is (1.0-50.0): (60.0-92.0), and the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I); the diluent is lactose monohydrate 316 and microcrystalline cellulose PH102, and the W / W mass ratio thereof is 1:1-3:1.

[0069] As a preferred embodiment, the pharmaceutical composition comprises an active ingredient and a diluent, and the W / W mass ratio thereof is (1.0-50.0): (60.0-92.0), and the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I); the diluent is lactose monohydrate 316 and microcrystalline cellulose PH101, and the W / W mass ratio thereof is 1:1-3:1.

[0070] As a further preferred embodiment, the pharmaceutical composition further comprises colloidal silicon dioxide as a glidant, and the content of colloidal silicon dioxide is 0.5% to 5.0% W / W relative to the total weight of the composition.

[0071] As a further preferred embodiment, the content of the glidant is 1.0% to 3.0% W / W relative to the total weight of the composition.

[0072] As a further preferred embodiment, the content of the glidant is 1.0% to 2.0% W / W relative to the total weight of the composition.

[0073] As a further preferred embodiment, the pharmaceutical composition further comprises magnesium stearate or sodium stearyl fumarate as a lubricant, with a content of 0.5% to 2.0% W / W relative to the total weight of the composition.

[0074] As a further preferred embodiment, the content of the lubricant is 0.5% to 1.5% W / W relative to the total weight of the composition.

[0075] As a further preferred embodiment, the pharmaceutical composition further comprises croscarmellose sodium as a disintegrant, and the content thereof is 0.5% to 5.0% W / W relative to the total weight of the composition.

[0076] As a further preferred embodiment, the content of the disintegrant is 1.0% to 5.0% W / W relative to the total weight of the composition.

[0077] As a preferred solution, the total content of each component in the pharmaceutical composition is 100 wt %.As a further preferred solution, the total content of the active ingredient, diluent, glidant, lubricant, and disintegrant is 100 wt %.

[0078] As a further preferred embodiment, the active ingredient, diluent, glidant, lubricant and disintegrant are as described above.

[0079] As a further preferred embodiment, in the pharmaceutical composition, the active ingredient is the hydrochloride monohydrate of the compound of formula (I), the diluents are microcrystalline cellulose PH102 and lactose monohydrate T80, the glidant is colloidal silicon dioxide 200, the lubricant is magnesium stearate, and the disintegrant is cross-linked carboxymethyl cellulose sodium.

[0080] As a further preferred embodiment, in the pharmaceutical composition, the active ingredient is the hydrochloride monohydrate of the compound of formula (I), the diluent is microcrystalline cellulose PH101 and lactose monohydrate 316, the glidant is colloidal silicon dioxide 200, the lubricant is magnesium stearate, and the disintegrant is cross-linked carboxymethyl cellulose sodium.

[0081] As a preferred solution, the pharmaceutical composition is a capsule.

[0082] As a further preferred embodiment, the unit dosage form of the capsule contains 1 mg to 500 mg of active ingredient, and the content of the active ingredient is calculated as the free base of the compound of formula (I).

[0083] As a further preferred embodiment, the unit dosage form of the capsule contains 1 mg to 200 mg of active ingredient, and the content of the active ingredient is calculated as the free base of the compound of formula (I).

[0084] As a further preferred embodiment, the unit dosage form of the capsule contains 1 mg, 5 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg or 200 mg of active ingredient, and the content of the active ingredient is calculated as the free base of the compound of formula (I).

[0085] A second aspect of the present invention provides a method for preparing a pharmaceutical composition, comprising the following steps:

[0086] Step A: Pre-treating the free base of the compound of formula (I) or its acid salt and the glidant by sieving them independently or after mixing; Pre-treating the diluent, disintegrant and lubricant by sieving them independently or after mixing;

[0087] Step B: uniformly mixing the free base of the compound of formula (I) or its acid salt and the glidant mixture prepared in step A with the pretreated diluent and disintegrant, and placing the mixture in a hopper mixer for mixing;

[0088] Step C: Evenly mix the mixed material prepared in step B and the pretreated lubricant, and place them in a mixing barrel for mixing.

[0089] As a preferred solution, the preparation method further comprises step D: capsule filling of the total mixed powder prepared in step C above.

[0090] As a preferred embodiment, the preparation method comprises: mixing the free base of the compound of formula (I) or its acid salt and the glidant and then pre-treating the mixture through a 50-80 mesh sieve; and / or, pre-treating the diluent independently through a 30-80 mesh sieve; and / or, pre-treating the disintegrant independently through a 30-50 mesh sieve; and / or, pre-treating the lubricant independently through a 20-40 mesh sieve.

[0091] As a preferred solution, in step A of the preparation method, the free base of the compound of formula (I) or its acid salt is pulverized.

[0092] The third aspect of the present invention relates to the use of the above-mentioned pharmaceutical composition in the preparation of CSF-1R inhibitor drugs.

[0093] The fourth aspect of the present invention relates to the use of the above-mentioned pharmaceutical composition in the preparation of a drug for treating tumors, autoimmune diseases, metabolic diseases or metastatic diseases associated with CSF1-R.

[0094] As a preferred embodiment, the tumor is cancer.

[0095] As a preferred embodiment, the tumor, autoimmune disease, metabolic disease or metastatic disease associated with CSF1-R is ovarian cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, kidney cancer, liver cancer, cervical cancer, bone metastatic cancer, papillary thyroid cancer, non-small cell lung cancer, colon cancer, gastrointestinal stromal tumors, solid tumors, melanoma, mesothelioma, glioblastoma, osteosarcoma, multiple myeloma, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, metastasis of primary tumor sites, myeloproliferative diseases, leukemia, rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, osteoporosis, hypereosinophilic syndrome, mastocytosis or mast cell leukemia.

[0096] The fifth aspect of the present invention relates to the above-mentioned pharmaceutical composition, which is used as a drug for treating tumors, autoimmune diseases, metabolic diseases or metastatic diseases associated with CSF1-R.

[0097] The present invention also provides a method for inhibiting CSF-1R activity, comprising administering an effective therapeutic amount of the pharmaceutical composition to a patient in need of treatment.

[0098] The present invention also provides a method for treating ovarian cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, kidney cancer, liver cancer, cervical cancer, bone metastatic cancer, papillary thyroid cancer, non-small cell lung cancer, colon cancer, gastrointestinal stromal tumors, solid tumors, melanoma, mesothelioma, glioblastoma, osteosarcoma, multiple myeloma, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, metastasis of primary tumor sites, myeloproliferative diseases, leukemia, rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, osteoporosis, hypereosinophilic syndrome, mastocytosis or mast cell leukemia associated with CSF1-R, the method comprising administering to a patient in need of treatment an effective therapeutic amount of the above-mentioned pharmaceutical composition. DETAILED DESCRIPTION

[0099] 1. Specific Definition

[0100] Detailed Description: Unless otherwise stated or specifically indicated, the following terms used in the specification and claims have the following meanings.

[0101] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable crystalline forms, salt forms, or prodrugs, along with other chemical components, and other components such as physiologically / pharmaceutically acceptable carriers. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredients and thereby exerting their biological activity.

[0102] The term "free base of a compound of formula (I)" refers to a compound of formula (I),

[0103] The term "active ingredient" refers to the free base of the compound of formula (I) or its acid salt; the active ingredient is preferably an anhydrate, hydrate or solvate of the free base of the compound of formula (I) or its acid salt; the solvent refers to an organic solvent selected from alcohols, chloroalkanes, ketones, ethers, cyclic ethers, esters, alkanes, cycloalkanes, benzenes, amides, sulfoxides or mixtures thereof, or aqueous solutions thereof. Preferably, the solvent is selected from methanol, ethanol, n-propanol, isopropanol, dichloromethane, acetonitrile, acetone, 1,4-dioxane, tetrahydrofuran, N,N-dimethylformamide, ethyl acetate, isopropyl acetate, methyl tert-butyl ether, 2-methoxyethyl ether or mixtures thereof, or aqueous solutions thereof.

[0104] The pharmaceutical composition of the present invention may include one or more pharmaceutically acceptable carriers, including but not limited to diluents, glidants, lubricants, disintegrants, binders, stabilizers, buffers, adjuvants, carriers, emulsifiers, viscosity modifiers, surfactants, preservatives, flavoring agents, or coloring agents. Medically acceptable excipients can be found in the examples described in the Handbook of Pharmaceutical Excipients by R.C. Rosenberg and P.J. Sheski.

[0105] As used herein, the term "diluent" refers to any pharmaceutically acceptable substance or composition added to a composition to increase bulk. Suitable diluents include, but are not limited to, lactose (e.g., lactose monohydrate, anhydrous lactose, or amorphous lactose), microcrystalline cellulose (e.g., PH101, PH102, PH301, PH302, PH200, Ceolus KG-802, Ceolus KG-1000, Ceolus UF-711, Ceolus UF-702, Prosolv SMCC 50, or SMCC90), silicified microcrystalline cellulose, mannitol, and dicalcium phosphate.

[0106] As used herein, the term "glidant" refers to any pharmaceutically acceptable substance or composition added to a composition to increase flowability. Suitable glidants include, but are not limited to, colloidal silicon dioxide, precipitated silicon dioxide, and / or talc.

[0107] As used herein, the term "lubricant" refers to any pharmaceutically acceptable agent added to a composition to reduce surface friction, lubricate the surface of the particles, reduce the tendency for static electricity to accumulate, and / or reduce the brittleness of the particles. Thus, a lubricant can act as an anti-agglomeration agent. Conventional lubricants include stearic acid and related compounds such as magnesium stearate and sodium stearyl fumarate. Alternative lubricants include glyceryl dibehenate, colloidal silica, talc, other hydrogenated vegetable oils, or triglycerides. Examples of suitable alternative lubricants include, but are not limited to, glyceryl dibehenate.

[0108] As used herein, the term "disintegrant" refers to a substance added to a composition to help it break down (disintegrate) and release the pharmaceutical agent. Examples of disintegrants include, but are not limited to, non-sugar water-soluble polymers such as cross-linked polyvinyl pyrrolidone. Other disintegrants that may also be used include, for example, cross-linked sodium carboxymethylcellulose, sodium starch glycolate, and the like, see, for example, Khattab (1992) J. Pharm. Pharmacol. 45: 687-691.

[0109] The terms "Lactose Monohydrate T80" and "Lactose Monohydrate 316" refer to block particles obtained by granulating lactose monohydrate powder. This specification indicates roughness and a large specific surface area.

[0110] The term "lactose monohydrate " is a spherical particle obtained by spray drying a lactose aqueous solution, and has a porous surface structure.

[0111] The term "silicified microcrystalline cellulose" is the English name of Silicified microcrystalline cellulose, which refers to microcrystalline cellulose and colloidal silicon dioxide mixed and dried in water. Calculated by weight of the dry product, it generally contains 94.0-100% microcrystalline cellulose.

[0112] 2. Experimental instruments and materials

[0113] 2.1 Instruments and Equipment

[0114] 2.2 Material Information

[0115] In order to objectively evaluate the compatibility problem of raw materials and the auxiliary materials used, the present invention selects the common auxiliary materials of oral solid preparations to be mixed with raw materials in different proportions, places different conditions, and takes appearance, hygroscopic weight gain, content and related substances as indicators after taking out at different time points to judge the compatibility of raw materials and auxiliary materials. According to the auxiliary materials manual, the auxiliary materials used are all common auxiliary materials of oral solid preparations, and have been included in the current edition of the Chinese Pharmacopoeia, and each auxiliary material is stable in nature. This experiment has been carried out a compatibility test on raw materials and each auxiliary material. The auxiliary material ratio is based on the "Basic Technical Guidance Principles for Research on Chemical Drug Preparations". The auxiliary material (such as microcrystalline cellulose) with a larger amount is set, and is mixed according to the weight ratio of raw materials: diluent=1:5; The auxiliary material (such as magnesium stearate) with a smaller amount is mixed according to the weight ratio of raw materials: lubricant=5:1. The samples were placed in high temperature (60℃, 40℃), high humidity (25℃ / 92.5%RH), accelerated (40℃ / 75%RH), light (visible light 4500Lux±500Lux, near ultraviolet light 85μw / cm 2 ) experimental conditions, sampling is conducted on day 0, day 10, day 30, and month 6. Samples are submitted for testing of relevant indicators (including appearance, moisture absorption weight gain, content, and related substances), and the test results are compared with those of the control sample API.

[0116] The results of the raw material and excipient compatibility test show that under high temperature 60℃, high humidity 25℃ / 92.5%RH, accelerated 40℃ / 75%RH and light conditions, the raw material has good compatibility with lactose monohydrate T80, lactose monohydrate 316, microcrystalline cellulose PH101, microcrystalline cellulose PH102, cross-linked sodium carboxymethyl cellulose, colloidal silicon dioxide 200, magnesium stearate and gelatin empty capsules.

[0117] 3. Dissolution assay method

[0118] 4. Content uniformity determination method

[0119] Several capsules prepared in Example 7 of the present application were taken, and the relative content of each capsule with the labeled amount as 100% was measured. The mean and standard deviation (SD%) and the absolute value of the difference between the labeled amount and the mean (A) were calculated. The content uniformity CP of the pharmaceutical composition of the present application was calculated by CP = A + 2.2S (CP ≤ 15.0 meets the requirements of the Chinese Pharmacopoeia).

[0120] Chromatographic conditions: Octadecylsilane bonded silica gel was used as filler (Waters C18, 4.6×150 mm, 3.5 μm chromatographic column); 0.1 vol% trifluoroacetic acid in water was used as mobile phase A, 0.1 vol% trifluoroacetic acid in acetonitrile was used as mobile phase B, isocratic elution was performed with mobile phase A-mobile phase B (60:40), the detection wavelength was 245 nm, the flow rate was 1.0 mL per minute, the column temperature was 40°C, the injection volume was 10 μL, and the run time was 7 minutes.

[0121] 5. Determination of related substances

[0122] Chromatographic conditions: Octadecylsilane bonded silica gel was used as filler (Waters C18+, 2.1×100 mm, 2.7 μm column, mobile phase A: 0.05 vol% trifluoroacetic acid in water (pH adjusted to 3.0 with triethylamine), mobile phase B: acetonitrile, detection wavelength: 245 nm, flow rate: 0.4 mL / min, column temperature: 25°C, injection volume: 2 μL. Gradient elution was performed as shown in the table below, with a run time of 24.1 minutes and a post-run time of 5 minutes.

[0123] The reagents in the embodiments of the present invention are known and commercially available. The reagents used are commercially available industrial or analytical grade reagents, or can be synthesized using methods known in the art. In particular, the free base of the compound of formula (I) is prepared according to patent application WO2018214867A1. Test methods not specifically described in the present invention are performed according to conventional techniques or methods in the art and are not listed here.

[0124] The present invention is further described in detail and completely in the following examples, which are only used to illustrate specific embodiments of the present invention and should not be interpreted as limiting the scope of the present invention in any way.

[0125] Example 1

[0126] (Evaluation of the flowability of pharmaceutical compositions)

[0127] 1. Existing technical problems

[0128] During the pharmaceutical research process, the inventors of this application found that the raw material had poor fluidity and low bulk density, which could not meet the requirements of GMP production. There was a risk of large differences in filling volume when filling capsules, which could not meet the requirements of capsule filling.

[0129] 2. Liquidity Assessment Plan

[0130] In view of the problems existing in the prior art, the inventors of the present application designed three specifications (5 mg, 25 mg and 100 mg) of pharmaceutical compositions and evaluated the fluidity of the pharmaceutical compositions by examining parameters such as bulk density, Carr's index and angle of repose.

[0131] The inventors mixed the raw material drug and colloidal silicon dioxide 200 according to the components and contents recorded in the table below and sieved them; added the sieved lactose monohydrate Or lactose monohydrate T80, microcrystalline cellulose PH102, and cross-linked carboxymethyl cellulose sodium are mixed evenly using a hopper mixer at a speed of 20 rpm for 15-45 minutes; then, sieved magnesium stearate is added and mixed evenly, and the mixture is placed in a total mixing barrel and mixed at a speed of 20 rpm for 3-6 minutes.

[0132] After preliminary process screening, we finally decided to use the powder direct filling process, examined the powder properties of the prescription, and used dissolution as the product indicator.

[0133] 3. Drug composition and content

[0134] Note: The formulation specifications in this application are based on the free base of the compound of formula (I). The actual "API" used is the hydrochloride monohydrate of the compound of formula (I), with a molecular weight of 474.95 and a free base molecular weight of 420.47. The conversion factor is 1.1296. Unless otherwise specified in the following examples, the API or API used is the same as that in Example 1.

[0135] 4. Powder properties data

[0136] From the above data, it can be seen that although the raw material has poor fluidity and low bulk density, the bulk density of the powder is significantly improved after being prepared into a pharmaceutical composition, and the angle of repose and Carr's index are significantly reduced. This can reduce the risk of large filling volume differences when filling capsules, and can meet the requirements of capsule filling, thereby facilitating the realization of the powder direct filling process.

[0137] Example 2

[0138] (Diluent Impact Assessment)

[0139] 1. Mixing uniformity inspection

[0140] 1.1 Drug components and content

[0141] The inventors prepared pharmaceutical compositions 2-1 to 2-4 according to the drug components and contents described in the following table and referring to the method of Example 1.

[0142] 1.2 Powder properties data

[0143] From the experimental results in the table above, we can see that lactose monohydrate The pharmaceutical compositions of lactose monohydrate T80 and compound diluents composed of lactose monohydrate T80 and microcrystalline cellulose PH102 or lactose monohydrate 316 and microcrystalline cellulose PH101 all have acceptable powder flowability. However, during the test, it was found that the diluent was lactose monohydrate. The powder mixture of the pharmaceutical composition containing lactose monohydrate T80, lactose monohydrate 316 and / or microcrystalline cellulose PH101, microcrystalline cellulose PH102 as diluents has uniform color and no risk of stratification.

[0144] 2. Investigation of fluidity and dissolution effect

[0145] 2.1 Drug components and content

[0146] The inventors prepared pharmaceutical compositions 2-5 to 2-9 according to the components and contents described in the following table and referring to the method of Example 1.

[0147] 2.2 Powder properties data

[0148] From the above experimental results, it can be seen that different pharmaceutical compositions containing lactose monohydrate T80 or lactose monohydrate 316 and / or microcrystalline cellulose PH102 or microcrystalline cellulose PH101 all have acceptable powder flowability.

[0149] 2.3 Drug dissolution results

[0150] The above experimental results show that different pharmaceutical compositions containing lactose monohydrate T80, lactose monohydrate 316, and / or microcrystalline cellulose PH101 or microcrystalline cellulose PH102 all have good dissolution behavior. Pharmaceutical compositions using a mixture of lactose monohydrate T80 and microcrystalline cellulose PH102 or lactose monohydrate 316 and microcrystalline cellulose PH101 as a diluent have even better dissolution behavior. In particular, the pharmaceutical composition using a mixture of lactose monohydrate 316 and microcrystalline cellulose PH101 as a diluent has a dissolution rate of over 90% in 5 minutes, indicating rapid onset of effect.

[0151] In particular, when the ratio of lactose monohydrate T80: microcrystalline cellulose PH102 is 2:1 or the ratio of lactose monohydrate 316: microcrystalline cellulose PH101 is 2:1 or 3:1, it not only has better dissolution behavior, but also has a larger bulk density and tap density, which is easier to fill.

[0152] Example 3

[0153] (Evaluation of the impact of glidants)

[0154] 1. Drug composition and content

[0155] The inventors prepared pharmaceutical compositions 3-1 to 3-6 according to the components and contents described in the following table and with reference to the method of Example 1, and investigated the dosage of the glidant.

[0156] 2. Powder properties data

[0157] 3. Drug dissolution results

[0158] The experimental results above demonstrate that a glidant dosage of 0.5% provides a good flow-enhancing effect. The angle of repose increases with increasing dosage, with a more pronounced increase at 3%. This indicates that excessive glidant dosage can affect powder flowability. Therefore, a colloidal silica dosage of 1% to 2% achieves optimal results. Drug dissolution results indicate that all three drug compositions containing colloidal silica within the 0.5% to 2.0% range exhibit rapid dissolution rates and good dissolution consistency in a pH 1.2 dissolution medium (0.1 mol / L hydrochloric acid solution).

[0159] Example 4

[0160] (Lubricant Impact Assessment)

[0161] 1. Drug composition and content

[0162] The inventors prepared pharmaceutical compositions 4-1 to 4-6 according to the components and contents described in the following table and with reference to the method of Example 1, and investigated the amount of lubricant used.

[0163] 2. Powder properties data

[0164] 3. Drug dissolution results

[0165] The powder properties data show that all three pharmaceutical compositions with different lubricant dosages exhibit good powder flowability, with the powder flowability trending toward improvement as the lubricant dosage increases. The drug dissolution results show that all three pharmaceutical compositions with magnesium stearate dosages ranging from 0.5% to 1.5% exhibit rapid dissolution rates and good dissolution consistency in a pH 1.2 dissolution medium (0.1 mol / L hydrochloric acid solution).

[0166] Example 5

[0167] (Evaluation of the impact of disintegrants)

[0168] 1. Drug composition and content

[0169] According to the components and contents described in the following table, pharmaceutical compositions 5-1 to 5-6 were prepared by referring to the method of Example 1, and the dosage of the disintegrant was investigated.

[0170] 2. Powder properties data

[0171] 3. Drug dissolution results

[0172] The above experimental results show that when the content of croscarmellose sodium as a disintegrant is within the range of 1% to 5%, the powder flowability is good, and different pharmaceutical compositions have a faster dissolution rate and good dissolution consistency in a dissolution medium of pH 1.2 (0.1 mol / L hydrochloric acid solution).

[0173] Example 6

[0174] (Development of small-scale preparations)

[0175] 1. Drug composition and content

[0176] Based on the 100 mg formulation composition ratio and test results of the pharmaceutical composition 5-2 in Example 5, the inventors prepared 5 mg and 25 mg formulation specifications of pharmaceutical compositions 6-1 and 6-2, and adjusted the amount of diluent to the filling amount while keeping the ratio of the glidant and lubricant unchanged. The process was consistent with that in Example 5.

[0177] 2. Drug dissolution effect

[0178] From the above test results, it can be seen that the pharmaceutical compositions of 5 mg and 25 mg small-scale preparations prepared using this method also have good dissolution behavior, which further illustrates that the prescription design is reasonable and meets the requirements of clinical research and drug marketing.

[0179] Example 7

[0180] (Formulation Development and Results)

[0181] 1. Prescription composition

[0182] The present invention provides a pharmaceutical composition of a CSF-1R inhibitor, prepared into capsules of three strengths: 5 mg, 25 mg, and 100 mg. The three strengths use different excipients in different types and proportions. The excipients include lactose monohydrate T80 / lactose monohydrate 316, microcrystalline cellulose PH101 / microcrystalline cellulose PH102, croscarmellose sodium, colloidal silicon dioxide 200, magnesium stearate, and empty gelatin capsules. The amounts of the components are shown in the following table:

[0183] 2. Preparation process

[0184] 1) Weighing: Weigh the drug substance (5 mg should be crushed in advance, 60 s), lactose monohydrate 316 (or lactose monohydrate T80), microcrystalline cellulose PH101 (or microcrystalline cellulose PH102), croscarmellose sodium, colloidal silicon dioxide 200, and magnesium stearate according to the prescribed amount.

[0185] 2) Screening of raw and excipients: The API and colloidal silicon dioxide 200 are sieved through a 60-mesh sieve for later use; microcrystalline cellulose PH101 (or microcrystalline cellulose PH102) is sieved through a 60-mesh sieve for later use; lactose monohydrate 316 (or lactose monohydrate T80) and cross-linked sodium carboxymethyl cellulose are sieved through a 40-mesh sieve for later use; and magnesium stearate is sieved through a 30-mesh sieve for later use.

[0186] 3) Main mixing: Place the raw materials and auxiliary materials except magnesium stearate in a hopper mixer and mix for 20 minutes at a mixing speed of 20 rpm to obtain the main mixed powder.

[0187] 4) Total mixing: Add magnesium stearate to the main mixed powder and mix for 5 minutes at a mixing speed of 20 rpm to obtain a total mixed powder.

[0188] 5) Discharging: Take out the mixed powder and place it in an LDPE bag.

[0189] 6) Capsule filling: Place the mixed powder in the capsule machine and fill it into opaque rich yellow 3# or 0# capsules.

[0190] 3. Preparation Analysis

[0191] Note: Take 10 capsules for content uniformity determination.

[0192] 4. Content uniformity study

[0193] The present applicants focused on studying the content uniformity of pharmaceutical compositions 7-2 and 7-4 during the final mixing, discharging, and capsule filling processes. The specific sampling times and methods for content uniformity testing included: 1) 11 samplings after final mixing; 2) sampling at the beginning, middle, and end of the discharging process; and 3) sampling 2-3 capsules at least every 5 minutes during the capsule filling process. The specific results are as follows:

[0194] 4.1 Determination of uniformity of blend content

[0195] 4.2 Determination of content uniformity during discharging

[0196] 4.3 Content uniformity determination during capsule filling process

[0197] The above experimental results show that the total mixing uniformity of pharmaceutical compositions 7-2 and 7-4 is good; during the discharging process, the content uniformity of pharmaceutical composition 7-4 is good, and pharmaceutical composition 7-2 has a tendency to stratify; during the capsule filling process, the content uniformity of pharmaceutical composition 7-4 is good, and the content fluctuation of pharmaceutical composition 7-2 is slightly large, and stratification obviously occurs.

[0198] 5. Stability study

[0199] In order to investigate the rationality and stability of the capsule formulation, preliminary influencing factors and stability studies were conducted on pharmaceutical compositions 7-1 to 7-4.

[0200] 5.1 Stability samples

[0201] 5.2 Sample placement conditions

[0202] 5.3 Stability data

[0203] From the above data, it can be seen that the accelerated conditions (40°C / 75% RH or 30°C / 65% RH) have no effect on the dissolution of capsules of various specifications.

[0204] 5.4 Related substances (%)

[0205] From the above data, it can be seen that the relevant substances in capsules of various specifications did not increase under a variety of different conditions and their properties were stable.

[0206] 5.5 Test conclusion

[0207] The present invention has developed a rapid-release capsule formulation of a CSF-1R inhibitor that can be directly filled using a powder-based process, using pharmaceutically acceptable excipients. The 5mg, 25mg, and 100mg dosage forms produced by the present invention meet critical quality attributes for release. Stability studies have shown that the product maintains relatively stable physical (dissolution) and chemical properties under accelerated storage conditions (40°C / 75% RH and 60°C) for 30 days and even after 6 months, meeting clinical standards. This excellent stability supports storage at room temperature.

[0208] The present invention underwent comprehensive and systematic product research, examining not only the type and dosage of functional excipients but also the feasibility and tolerance range of key process parameters. The direct powder filling process employed in this invention offers advantages such as fewer production steps, reduced time and labor costs, and ease of scale-up, enabling the production of a uniform, stable formulation with excellent release properties.

[0209] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above disclosure, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the free base of the compound of formula (I) or its acid salt as an active ingredient, a pharmaceutically acceptable diluent, and other pharmaceutically acceptable carriers, wherein the other pharmaceutically acceptable carriers are one or more of a glidant, a lubricant and a disintegrant, 2. The pharmaceutical composition according to claim 1, characterized in that The acid salt of the compound of formula (I) is selected from hydrochloride, sulfate, hydrobromide, hydrofluoride, hydroiodide, phosphate, acetate, dichloroacetate, trichloroacetate, trifluoroacetate, benzenesulfonate, p-toluenesulfonate, 4-chlorobenzenesulfonate, 1,5-naphthalene disulfonate, naphthalene-2-sulfonate, ethane-1,2-disulfonate, methanesulfonate, ethanesulfonate, benzoate, decanoate, hexanoate, caprylate, cinnamate, citrate, cyclohexanesulfamic acid salt, camphorsulfonate, aspartate, camphorate, gluconate, glucuronate, glutamate, isoascorbate, lactate, aspartate, malate, mandelate, pyroglutamate, tartrate, dodecanedione, tartrate, pyroglutamate ... alkyl sulfate, dibenzoyltartrate, formate, fumarate, galactonate, gentisate, acetohydroxamate, malonate, succinate, glutarate, adipate, sebacate, 2-ketoglutarate, glycolate, hippurate, isethionate, lactobionate, ascorbate, aspartate, laurate, camphorate, maleate, nicotinate, oleate, orotate, oxalate, palmitate, pamoate, propionate, 4-acetamidobenzoate, 4-aminobenzoate, salicylate, 4-aminosalicylate, 2,5-dihydroxybenzoate, 1-hydroxy-2-naphthoate, stearate, thiocyanate, undecylenate, or succinate; Preferably, the acid salt of the compound of formula (I) is selected from hydrochloride, sulfate, phosphate, methanesulfonate, citrate, malate, fumarate or tartrate.

3. The pharmaceutical composition according to claim 1 or 2, characterized in that The active ingredient is an anhydrate, hydrate or solvate of the free base of the compound of formula (I) or its acid salt; Preferably, the active ingredient is a solvate of the free base of the compound of formula (I) or its acid salt, and the solvent is selected from alcohols, chloroalkanes, ketones, ethers, cyclic ethers, esters, alkanes, cycloalkanes, benzenes, amides, sulfoxides, organic solvents or mixtures thereof, or aqueous solutions thereof; More preferably, the active ingredient is a solvate of the free base of the compound of formula (I) or its acid salt, and the solvent is selected from methanol, ethanol, n-propanol, isopropanol, dichloromethane, acetonitrile, acetone, 1,4-dioxane, tetrahydrofuran, N,N-dimethylformamide, ethyl acetate, isopropyl acetate, methyl tert-butyl ether, 2-methoxyethyl ether or a mixture thereof, or an aqueous solution thereof; Preferably, the active ingredient is an anhydrate or hydrate of a free base or an acid salt thereof; More preferably, the active ingredient is an anhydrate of the free base or its acid salt; More preferably, the active ingredient is a hydrate of a free base or an acid salt thereof, and each molecule of the hydrate contains 1 to 3 water molecules; More preferably, the active ingredient is a hydrate of a free base or an acid salt thereof, and each molecule of the hydrate contains one water molecule.

4. The pharmaceutical composition according to claim 1, characterized in that The content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I), and the pharmaceutical composition contains 0.1% to 60.0% W / W of the active ingredient relative to the total weight of the composition; Preferably, it contains 1.0% to 40.0% W / W of active ingredient relative to the total weight of the composition; More preferably, the active ingredient is contained in an amount of 3.0% to 32.0% W / W relative to the total weight of the composition.

5. The pharmaceutical composition according to claim 1, characterized in that The diluent is one or more of lactose, lactose hydrate and microcrystalline cellulose; In particular, the pharmaceutical composition comprises 40.0% to 99.9% W / W of diluent relative to the total weight of the composition; Preferably, the diluent comprises 50.0% to 94.0% W / W relative to the total weight of the composition; More preferably, the diluent is contained in an amount of 60.0% to 92.0% W / W relative to the total weight of the composition.

6. The pharmaceutical composition according to claim 5, characterized in that The diluent is a mixture of lactose monohydrate and microcrystalline cellulose, and the W / W mass ratio of the lactose monohydrate and the microcrystalline cellulose is 1:5 to 5:1; preferably, the W / W mass ratio of the lactose monohydrate and the microcrystalline cellulose is 1:3 to 3:1; more preferably, the W / W mass ratio of the lactose monohydrate and the microcrystalline cellulose is 1:1 to 3:

1.

7. The pharmaceutical composition according to claim 6, characterized in that The lactose monohydrate is lactose monohydrate T80 or lactose monohydrate 316; the microcrystalline cellulose is microcrystalline cellulose PH102 or microcrystalline cellulose PH101.

8. The pharmaceutical composition according to claim 7, characterized in that The diluent is a mixture of lactose monohydrate T80 and microcrystalline cellulose PH102, and the W / W mass ratio of the lactose monohydrate T80 and the microcrystalline cellulose PH102 is 1:5 to 5:1; preferably, the W / W mass ratio of the lactose monohydrate T80 and the microcrystalline cellulose PH102 is 1:3 to 3:1; more preferably, the W / W mass ratio of the lactose monohydrate T80 and the microcrystalline cellulose PH102 is 1:1 to 3:

1.

9. The pharmaceutical composition according to claim 7, characterized in that The diluent is a mixture of lactose monohydrate 316 and microcrystalline cellulose PH101, and the W / W mass ratio of the lactose monohydrate 316 and the microcrystalline cellulose PH101 is 1:5 to 5:1; preferably, the W / W mass ratio of the lactose monohydrate 316 and the microcrystalline cellulose PH101 is 1:3 to 3:1; more preferably, the W / W mass ratio of the lactose monohydrate 316 and the microcrystalline cellulose PH101 is 1:1 to 3:

1.

10. The pharmaceutical composition according to claim 1, characterized in that The glidant is one or more of colloidal silicon dioxide, precipitated silicon dioxide and talc; Preferably, the glidant is colloidal silicon dioxide; More preferably, the glidant is colloidal silicon dioxide 200; In particular, the pharmaceutical composition comprises 0.1% to 10.0% W / W of a glidant relative to the total weight of the composition; Preferably, the composition comprises 0.5% to 5.0% W / W of a glidant relative to the total weight of the composition; More preferably, the glidant is contained in an amount of 1.0% to 3.0% W / W relative to the total weight of the composition.

11. The pharmaceutical composition according to claim 1, characterized in that The lubricant is one or more of magnesium stearate, sodium stearyl fumarate, glyceryl dibehenate, colloidal silicon dioxide, talc, other hydrogenated vegetable oils and triglycerides; Preferably, the lubricant is one or more of magnesium stearate, sodium stearyl fumarate, and glyceryl dibehenate; More preferably, the lubricant is magnesium stearate or sodium stearyl fumarate; In particular, the pharmaceutical composition comprises 0.1% to 5.0% W / W of lubricant relative to the total weight of the composition; Preferably, it comprises 0.5% to 2.0% W / W of lubricant relative to the total weight of the composition; More preferably, the lubricant is contained in an amount of 0.5% to 1.5% W / W relative to the total weight of the composition.

12. The pharmaceutical composition according to claim 1, characterized in that The disintegrant is one or more of cross-linked carboxymethylcellulose sodium, cross-linked polyvinyl pyrrolidone, sodium starch glycolate and the like; Preferably, the disintegrant is croscarmellose sodium; In particular, the pharmaceutical composition comprises 0.1% to 10.0% W / W of a disintegrant relative to the total weight of the composition; Preferably, the composition comprises 0.5% to 5.0% W / W of a disintegrant relative to the total weight of the composition; More preferably, the disintegrant is contained in an amount of 1.0% to 5.0% W / W relative to the total weight of the composition.

13. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition comprises an active ingredient and a diluent, and the W / W mass ratio thereof is (1.0-50.0):(50.0-94.0), and the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I); the diluent is lactose monohydrate and microcrystalline cellulose, and the W / W mass ratio thereof is 1:1-3:

1.

14. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition comprises an active ingredient and a diluent, and the W / W mass ratio thereof is (1.0-50.0):(60.0-92.0), and the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I); the diluent is lactose monohydrate T80 and microcrystalline cellulose PH102, and the W / W mass ratio thereof is 1:1-3:

1.

15. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition comprises an active ingredient and a diluent, and the W / W mass ratio thereof is (1.0-50.0):(60.0-92.0), and the content of the active ingredient is calculated as the hydrochloride monohydrate of the compound of formula (I); the diluent is lactose monohydrate 316 and microcrystalline cellulose PH101, and the W / W mass ratio thereof is 1:1-3:

1.

16. The pharmaceutical composition according to any one of claims 13 to 15, characterized in that The pharmaceutical composition further comprises colloidal silicon dioxide as a glidant, the content of which is 0.5% to 5.0% W / W relative to the total weight of the composition; preferably 1.0% to 3.0% W / W; and / or, The pharmaceutical composition further comprises magnesium stearate or sodium stearyl fumarate as a lubricant, the content of which is 0.5% to 2.0% W / W relative to the total weight of the composition; preferably 0.5% to 1.5% W / W; and / or, The pharmaceutical composition further comprises cross-linked carboxymethyl cellulose sodium as a disintegrant, and the content thereof is 0.5% to 5.0% W / W relative to the total weight of the composition; preferably 1.0% to 5.0% W / W.

17. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition is a capsule.

18. The pharmaceutical composition according to claim 17, characterized in that The unit dosage form of the capsule contains 1 mg to 500 mg of active ingredient, and the content of the active ingredient is calculated as the free base of the compound of formula (I); Preferably, the unit dosage form contains 1 mg to 200 mg of active ingredient, the content of the active ingredient being calculated as the free base of the compound of formula (I); More preferably, the unit dosage form contains 1 mg, 5 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg or 200 mg of active ingredient, calculated as the free base of the compound of formula (I).

19. A method for preparing the pharmaceutical composition according to claim 1, characterized in that: The following steps are involved: Step A: Pre-treating the free base of the compound of formula (I) or its acid salt and the glidant by sieving them independently or after mixing; Pre-treating the diluent, disintegrant and lubricant by sieving them independently or after mixing; Step B: uniformly mixing the free base of the compound of formula (I) or its acid salt and the glidant mixture prepared in step A with the pretreated diluent and disintegrant, and placing the mixture in a hopper mixer for mixing; Step C: uniformly mixing the mixed material prepared in step B and the pretreated lubricant, and placing them in a main mixing barrel for mixing; Optionally, step D: capsule filling the total mixed powder prepared in the above step C.

20. The preparation method according to claim 19, characterized in that: The free base of the compound of formula (I) or its acid salt and the glidant are mixed and pre-treated through a 50-80 mesh sieve; and / or, the diluent is pre-treated through a 30-80 mesh sieve independently; and / or, the disintegrant is pre-treated through a 30-50 mesh sieve independently; and / or, the lubricant is pre-treated through a 20-40 mesh sieve independently.

21. The preparation method according to claim 19, characterized in that: In step A, the free base or acid salt of the compound of formula (I) is pulverized.

22. Use of the pharmaceutical composition according to any one of claims 1 to 18 in the preparation of a CSF-1R inhibitor drug.

23. Use of the pharmaceutical composition according to any one of claims 1 to 18 in the preparation of a drug for treating tumors, autoimmune diseases, metabolic diseases or metastatic diseases associated with CSF1-R; preferably, the tumor is cancer.

24. The use according to claim 23, characterized in that the tumor, autoimmune disease, metabolic disease or metastatic disease associated with CSF1-R is a drug for ovarian cancer, pancreatic cancer, prostate cancer, lung cancer, breast cancer, kidney cancer, liver cancer, cervical cancer, bone metastatic cancer, papillary thyroid cancer, non-small cell lung cancer, colon cancer, gastrointestinal stromal tumors, solid tumors, melanoma, mesothelioma, glioblastoma, osteosarcoma, multiple myeloma, hyperproliferative diseases, metabolic diseases, neurodegenerative diseases, metastasis of primary tumor sites, myeloproliferative diseases, leukemia, rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, multiple sclerosis, autoimmune nephritis, lupus, Crohn's disease, asthma, chronic obstructive pulmonary disease, osteoporosis, hypereosinophilic syndrome, mastocytosis or mast cell leukemia.

25. The pharmaceutical composition according to any one of claims 1 to 18, for use as a medicament for treating tumors, autoimmune diseases, metabolic diseases or metastatic diseases associated with CSF1-R.

Citation Information

Patent Citations

  • Preparation method of CSF-1R inhibitor or acid salt thereof

    CN115385897A

  • Pyrrolopyrimidine derivatives useful in cancer treatment

    WO2005116035A1

  • N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof

    WO2018214867A1

  • Acid salt of crystalline CSF-1r inhibitor, and preparation method therefor and use thereof

    WO2022247786A1